&nbsp;

WhyQuitSmokingBeforeYourSurgery.pdf

Jan 2021

Document

WhyQuitSmokingBeforeYourSurgery-FR.pdf

Jan 2021

What you need to know about COVID-19 vaccines: Information for people with cancer

Emplacements du programme ontarien de dépistage pulmonaire

Le dépistage du cancer du poumon par l'intermédiaire du Programme ontarien de dépistage du cancer du poumon est disponible pour les personnes...

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2020

Status: Current
ID: PET 2020-2

May 2021

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

ERDA

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

erdafitinib (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2021

Regimen

ENHE

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Document

EndometrialCancerDiagnosisPathwayMap.pdf

Dec 2021

Document

EndometrialCancerTreatmentPathwayMap.pdf

Dec 2021

Regimen

ENTR

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

entrectinib - For the treatment of locally advanced (not amenable to curative therapy) or metastatic NSCLC, according to clinical criteria

Drugs Used:

entrectinib